For the majority of these patients, APOL1 status or other rare variants associated with their kidney disease [48] are arguably more relevant to their immediate health, and like other healthy and patient populations receiving results, it is unclear what potential benefits would be realized if additional genetic data were returned to this already burdened patient population. This evidence concerns the gene APOL1 and kidney disorder.